A Phase 3 trial of HIPEC in Ovarian Cancer

Interval cytoreduction with HIPEC (Hyperthermic Intraperitoneal chemotherapy) signficantly improves Recurrence free survival and overall survival when compared to surgery without HIPEC in stage 3 epithelial ovarian cancer

You can find the abstract here



DESKTOP III Trial -ASCO 2017 Abstract

Results of DESKTOP III ( Progression Free Survival) have been published recently in ASCO Abstracts

The median Progression free survival in patients undergoing secondary cytoreduction for relapsed ovarian cancer (with 6 months plus platinum free interval, positive AGO score ie., ECOG 0,<500 mL Ascites, complete resection at first surgery) was 19.6 months versus 14 months without surgery.

The abstract can be accessed here



Bilateral Oophorectomy and breast cancer risk in BRCA 1 and BRCA 2 mutation carriers

Findings from a prospective study has suggested that prophylactic oophorectomy may play a role in prevention of premenopausal breast cancer in BRCA 2 mutation carriers but not in BRCA 1 .

You can find the link to the study here